Skip to main content
PMC home page
Scientific Reports logoLink to Scientific Reports
. 2016 Jan 6;6:18633. doi: 10.1038/srep18633

VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model

Lucila Gallino 1,*, Guillermina Calo 1,*, Vanesa Hauk 1, Laura Fraccaroli 1, Esteban Grasso 1, Mónica Vermeulen 2, Claudia Pérez Leirós 1, Rosanna Ramhorst 1,a
PMCID: PMC4702085  PMID: 26733206

Abstract

Successful embryo implantation occurs followed by a local pro-inflammatory response subsequently shifted toward a tolerogenic one. VIP (vasoactive intestinal peptide) has embryotrofic, anti-inflammatory and tolerogenic effects. In this sense, we investigated whether the in vivo treatment with VIP contributes to an immunosuppressant local microenvironment associated with an improved pregnancy outcome in the CBA/J × DBA/2 resorption prone model. Pregnancy induced the expression of VIP, VPAC1 and VPAC2 in the uterus from CBA/J × DBA/2 mating females on day 8.5 of gestation compared with non-pregnant mice. VIP treatment (2 nmol/mouse i.p.) on day 6.5 significantly increased the number of viable implantation sites and improved the asymmetric distribution of implanted embryos. This effect was accompanied by a decrease in RORγt and an increase in TGF-β and PPARγ expression at the implantation sites. Moreover, VIP modulated the maternal peritoneal macrophages efferocytosis ability, tested using latex beads-FITC or apoptotic thymocytes, displaying an increased frequency of IL-10-producer F4/80 cells while did not modulate TNF-α and IL-12 secretion. The present data suggest that VIP treatment increases the number of viable embryos associated with an increase in the efferocytic ability of maternal macrophages which is related to an immunosuppressant microenvironment.

From the perspective of the immune system, pregnancy involves the generation of a sterile inflammatory response that will be physiologically limited in its extent and duration by several immunoregulatory mechanisms1,2. This pro-inflammatory response is accompanied by tissue remodeling at the implantation site, associated with apoptosis processes that generate a cell turn over implicated in the maintenance of tissue homeostasis and allowing trophoblast invasion into maternal decidua3,4. Maternal immune system had to evolve mechanisms for tissue homeostasis maintenance in a tolerogenic microenvironment including the participation of specialized leukocyte subpopulations, such as regulatory T cells (Treg), uterine NK cells, decidual macrophages activated in an alternative profile and tolerogenic dendritic cells5,6,7 as well as various cytokines, chemokines, galectins and immune polypeptides8,9.

In this sense, the specialized Treg population (CD4 + CD25 + Foxp3+), essential for maternal tolerance of the conceptus, is stimulated through antigen-specific and antigen non-specific pathways thus exerting their suppressive actions in the critical peri-implantation phase of pregnancy10. This local tolerogenic microenvironment is also accompanied by a decrease in T-bet (transcriptor factor associated with a Th1 profile) and RORγt expression (transcription factor associated with a Th17 profile) in several ex vivo and mice models11,12,13,14,15. In humans, low frequency of Th17 cells was reported in the decidua in comparison to blood during early pregnancy13,16; and also a systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells13.

Consistently with a tolerogenic microenvironment, maternal macrophages present a predominant alternative activation profile contributing to the production of IL-10 and TGFβ, wound healing mediators synthesis and the clearance of apoptotic bodies5,17. In this sense, the efferocytosis, or engulfment of apoptotic cells by macrophages, is an essential process that contributes to tissue homeostasis with a profound influence on inflammation resolution, through secretion of anti-inflammatory cytokines, such as TGF-β and IL-105,17,18.

In this intricate network generated by maternal leukocytes at the maternal-placental interface, the role of the immune peptides is to allow the communication between immune and trophoblast cells8.

Particularly VIP, vasoactive intestinal peptide, mediates immune and nervous effector functions and has emerged as a potential effective treatment for inflammatory and autoimmune disorders based on its anti-inflammatory and tolerogenic effects11,18,19 as it was demonstrated in mouse models of inflammation through its action on macrophages and T cell VPAC receptors20,21,22.

In the feto-maternal context, VIP is present in viable implantation sites of normal mice where it induces an increase in Treg frequency12. However, lower levels of VIP and Foxp3 were found in implantation sites of prediabetic NOD (non-obese diabetic) mice, which are characterized by a Th1 systemic cytokine profile, correlating with a reduction in litter size and increased resorption rates23. In fact, pregnant NOD mice treated with VIP at gestational day 6.5, show a modulation of inflammatory signals at the early maternal-fetal interface and a partial improvement in the pregnancy outcome12.

Since the control of the initial inflammatory response after embryo implantation is crucial for a successful pregnancy outcome1,2 and considering that VIP mediates anti-inflammatory and tolerogenic immune effects, we hypothesized that VIP participates in homeostasis maintenance at the early maternal-placental interface inducing an immunosuppresant microenvironment through maternal macrophage efferocytosis associated with an alternative activation profile. The mating of CBA/J females (H2k) with DBA/2 males (H2d) provokes spontaneously high resorption rates associated with a failure in the maternal tolerogenic response, whereas mating CBA/J females with BALB/c mice, which also bear H2d antigens, ends in completely normal pregnancies offering the possibility to elucidate immunological mechanisms and modify them through different drug treatments24. In line with this, we propose that VIP treatment at the early post implantation window of pregnant CBA/J × DBA/2 mouse mating, would induce an immunosuppressant local microenvironment that could contribute to reach certain end-points of normal gestation, such as the number of viable embryo and a symmetric distribution along the uterine horns.

Results

VIP/VPAC system expression at the feto-maternal interface in CBA/J × DBA/2 matings: characterization in viable implantation sites

CBA/J × DBA/2 mating is a well-studied model of immunologically mediated peri-implantation pregnancy loss that shares features with human pregnancy complications. Embryos derived from mating CBA/J females with DBA/2 males showed an increased frequency of resorption rates compared with other strains or strain combinations25,26. Embryonic lethality in this mating is due to the rejection of the semiallogeneic placenta by several altered maternal immune mechanisms, such as a reduction in Treg frequency24.

First of all, we studied the expression of VIP and its high affinity receptors (VPAC1 and VPAC2) in viable implantation sites. As shown in Fig. 1A,B, pregnancy significanlty increase the expression of VIP and their receptors, VPAC1 and VPAC2. To assess if VPACs were functional, the implantation site explants were cultured in the absence/presence of VIP (100 nM) during 24 h and the expression of IL-17 and the transcription factor RORγt were evaluated by RT-PCR. As an additional control implantation sites from CBA/J females after mating with BALB/c male at the same gestational age were used. Figure 1C,D, show that the treatment with VIP in vitro, significantly reduced IL-17 and RORγt expression at the implantation sites. In fact, in those cultures performed in the absence of VIP, CBA/J × DBA/2 implantation sites displayed higher IL-17 and RORγt expression compared with those in the control mating cultured under the same conditions. The present results show that implantation sites of CBA/J × DBA/2 mating have a functional VIP/VPAC system and also suggest that they display an exacerbated Th17 profile in comparison with the control that can be modulated in vitro by VIP.

Figure 1. VIP/VPAC system at the feto-maternal interface in CBA/J × DBA/2 mating.

Figure 1

Open in a new tab

Pregnant CBA/J ×DBA/2 females or CBA non pregnant mice were sacrificed at 8.5 day of gestation and implantation sites were obtained. (A) VIP and (B) VPAC receptors were evaluated by RT-PCR as described in Mat erial and Methods (C) Implantation site explants isolated from CBAxDBA or CBAxBALB/c matings were cultured in the absence/presence of VIP (100 nM) during 24 h and IL-17 and RORγt were evaluated by RT-PCR. Bands were semi-quantified with ImageJ® and intensity expressed in arbitrary units (AU) relative to GAPDH. Values represent mean ± S.E.M of at least 3 experiments (Mann Whitney test *p < 0.05).

In vivo VIP treatment increases the number of viable implantation sites and improves their asymmetric distribution

This pregnancy model with high resorption rates enables the evaluation of an immunomodulatory treatment and the study of different end points of pregnancy outcome as well as the isolation of implantation sites for further analysis. Therefore, CBA/J × DBA/2 female were treated in vivo with an intraperitoneal injection of VIP (2 nmol/mouse) or PBS (as control) in the early post-implantation period (at 6.5 day of gestation).

Figure 2A shows that VIP treatment significantly increased the number of viable implantation sites (day 8.5) in comparison with PBS-treatment, while did not modulate the number of sites with resorption. In addition, an improvement in the asymmetric distribution of implanted embryos was observed (Fig. 2B).

Figure 2. In vivo VIP treatment increases the number of viable implantation sites and improves the asymmetric distribution.

Figure 2

Open in a new tab

CBA/J × DBA/2 females were treated in vivo with VIP (2 nmol/mouse) or PBS i.p. at day 6.5 of gestation. At d8.5 females were sacrificed and (A) number of viable implantation sites and (B) the asymmetric distribution of implanted embryos were evaluated as described in Material and Methods. Values are media ± S.E. of viable sites counted in 8 mice (control group), 18 mice (CBAxDBA, PBS group) and 15 mice (CBAxDBA, VIP group).

VIP treatment decreases RORγt while increases tolerogenic mediators expression at the implantation sites

In line with the previous results, we analyzed whether VIP in vivo treatment could modulate the immune microenvironment at the implantation sites. CBA/J × DBA/2 pregnant mice were treated in vivo with VIP or PBS, as described, and at day 8.5 the implantation sites were obtained and Foxp3/RORγt expression ratio was evaluated by RT-PCR. Figure 3A shows that VIP treatment induced a significant decrease in RORγt expression, implying that the Treg/Th17 ratio is increased.

Figure 3. VIP treatment increases the Treg/Th17 ratio and the expression of tolerogenic mediators at the implantation sites.

Figure 3

Open in a new tab

CBA/J × DBA/2 pregnant mice were treated in vivo with 2 nmol/mouse VIP or PBS i.p. at day 6.5 and the implantation sites were obtained at day 8.5. (A) Foxp3 and RORγt expression and (B) TGF-β and PPARγ expression were evaluated by RT-PCR. Bands were semi-quantified with ImageJ® and intensity expressed in arbitrary units (AU) relative to GAPDH. Values represent mean ± S.E.M of at least 3 experiments (Mann Whitney test *p < 0.05).

Moreover, we investigated TGF-β and PPARγ expression, on the knowledge that TGF-β is not only a pro-implantatory mediator but it is also associated with suppressor functions; and that PPARγ increased expression and/or activity is essential for the acquisition of alternative activation in macrophages27,28. Figure 3B shows that VIP treatment increased the expression of both tolerogenic markers, suggesting that VIP treatment induces a local tolerogenic microenvironment that would increase the number of viable embryos.

VIP treatment increases maternal macrophage efferocytosis

The constitution of the maternal-placental interface involves apoptosis of trophoblast cells, smooth muscle and endothelial cells that, in turn, requires an immediate clearance of apoptotic cells by macrophages and their activation in an alternative profile (to prevent a deleterious inflammatory response)5,29. Hence, we first explored whether the treatment of CBA/J × DBA/2 pregnant mice with VIP could modulate the efferocytic ability of maternal macrophages using two complementary approaches: the efferocytosis of apoptotic thymocytes and of latex beads.

For the first approach, the efferocytosis of apoptotic thymocytes, maternal macrophages were recovered at day 8.5 after in vivo treatment with VIP, as previously described, and were co-cultured with syngeneic thymocytes induced to apoptosis. After, 30, 60, 90 and 120 min cells were stained with Hematoxilin–Eosin and analyzed by microscopy. As describes Fig. 4A, VIP treatment significantly increased the % of efferocytosis after 60 and 90 min of incubation with apoptotic thymocytes. This was accompained by a signficant increase in the phagocytic index (Fig. 4B). Figure 4C shows representative microphotographs of macrophages recovered from pregnant CBA/J treated with PBS or VIP after apoptotic thymocytes engulfment.

Figure 4. VIP treatment increases the maternal macrophage efferocytosis ability.

Figure 4

Open in a new tab

Peritoneal macrophages from CBA/J × DBA/2 females were recovered at 8.5 day of gestation and cultured with syngeneic thymocytes induced to apoptosis in the absence or presence of VIP (10 nM). After, 30, 60, 90 and 120 min cells were stained with Hematoxilin–Eosin and the (A) % of efferocytosis and (B) the phagocytic index were analyzed by microscopy. (C) Representative images of macrophages recovered from pregnant CBA/J treated with PBS or VIP after apoptotic thymocytes engulfment. (D) Maternal peritoneal macrophages were recovered at day 8.5 after in vivo treatment with VIP or PBS and cultured with with latex-beads-FITC conjugated. After 90 min the percentage of efferocytosis was quantified by FACS analysis. (E) Representative dot plot profile previous and after the efferocytosis assay in absence or presence of VIP.

With the second approach, we could observe that the in vitro treatment with VIP increased the phagocytosis of latex beads by maternal macrophages, strongly suggesting that the increase in the efferocytosis observed in peritoneal macrophages was due to a direct effect of the peptide when injected to pregnant mice (Fig. 4D). Figure 4E shows a representative dot plot profile previous and after the efferocytosis assay in absence or presence of VIP.

VIP treatment modulates macrophage cytokine production

Finally, we evaluated whether VIP treatment in vivo modulates the profile of cytokines produced by maternal macrophages from CBA/J pregnant mice. Therefore, after the efferocytosis assay, macrophages from pregnant CBA/J mice treated with PBS or VIP were washed and remained in culture for additional 24 h, then supernatants were collected for ELISA determinations and cells recovered for FACS analysis.

As shown in Fig. 5A, the control mice that were not treated with VIP had higher levels of IL-12 while the CBA/J group treated with VIP did not modulate IL-12 levels (Fig. 5A). The same pattern of secretion was observed for TNF-α (Fig. 5B). In contrast, VIP treatment increased the frequency of F4/80 + IL10+ cells even before the efferocytosis assay, suggesting that VIP treatment might modulate maternal macrophages in vivo (Fig. 5C).

Figure 5. VIP treatment modulates macrophage cytokine production After the efferocytosis assay, macrophages from pregnant CBA/J mice treated with PBS or VIP (2 nmol/mouse) were washed and remained in culture for additional 24 h, then supernatants were collected and (A) IL-12 and (B) TNF-α were quantified by ELISA.

Figure 5

Open in a new tab

(C) Cells were recovered and the frequency of F4/80 + IL-10+ analyzed by FACS. The left pannel shows representative dot plot with the frequency of of F4/80 + IL-10 from famele treated in vivo with PBS or VIP, previous and after the efferocytosis assay.

Discussion

Homeostasis maintenance at the feto-maternal interface is the result of multiple processes that occur at local and systemic levels which require several ongoing signals and checkpoints. Immune cells involved in the control of the early inflammatory response have a central role at the maternal-placental interface such as the activation of macrophages in an alternative profile or M2 instead of the classical inflammatory profile or M15,17. In the present work, we analyzed the immunoregulatory role of VIP in the CBA/J × DBA/2 mating with high resorption rate associated with a failure in the tolerogenic maternal response. The present results provide new data on the in vivo treatment with VIP, which prevents embryo resorption and improves pregnancy end points evidenced as an increase in the number of viable embryo with a symmetric distribution in the uterine horns.

The ability of VIP to improve pregnancy outcome is based in its immunomodulatory effects observed not only in the in vitro treatment of the implantation site explants with VIP but also in the in vivo treatment of pregnant mice at the early post implantation period. On the one hand, VIP decreased the Th17 response reflected by a reduction in IL-17 and RORγ expression after in vitro and in vivo treatments. This effect was accompained by an increase in the expression of immuno suppressor modulators as TGF-β and PPARγ at the implantation sites. On the other hand, VIP modulated the efferocytosis of macrophages evaluated by two complementary approaches, the efferocytosis of latex beads and of apoptotic thymocytes. In addition, VIP treatment in vivo increased the frequency of F4/80+ IL-10-producing cells suggesting their activation in an alternative profile.

VIP immunomodulatory effect has been observed in the NOD mice, evidenced by the induction IL-10, TGF-β and Foxp3 expression at the implantation sites. In addition, implantation sites undergoing resorption processes showed lower VIP expression along with a lower expression of these cytokines and the transcription factor Foxp3, higher prostaglandin synthesis and higher expression of IL-17 and RORγt12,30.

Recently, Obermajer et al. demonstrated the conversion of Th17 cells into Treg by which mesenchymal stem cells induced myeloid-derived immunosuppressive cells that mediate operational transplant tolerance. They demonstrated that RORγ is a common factor in the differentiation of Treg and Th17 cells in mice, and the identification of IL-17A + Foxp3+ cells that then converts into a IL-17A-Foxp3+ cell strongly argues for direct conversion of Th17 cells into Treg cells31. Here, in the CBAxDBA model, we show that VIP treatment decreased RORγ and slightly increase Foxp3 expression. However, whether this new mechanism of immune regulation operates at the feto-maternal interface is still an open question.

With respect to the distribution of intrauterine embryo implantation sites, in most mammalian species shows remarkably constant patterns. In rodents, embryos implant evenly along the uterine horns and the disruption of these patterns can have adverse effects on pregnancies. Chen Q. et al., describe diverse molecular factors, such as steroid hormone signaling, lipid signaling, adrenergic signaling, developmental genes, ion/water channels, and potentially embryonic signaling are actively involved in intrauterine embryo distribution32; even VIP treatment improve symmetric distribution it will be interesting to investigate VIP efects on this potential mediators.

Regarding macrophage phenotypes, the classification is useful but represents an over simplification due to their substantial plasticity programming during the course of an inflammatory response, with markers and functions readily altered by external signals.

The activation of macrophages in an alternative profile has been associated with enhanced efferocytosis of apoptotic cells preventing the release of intracellular contents that can contribute to inflammation and autoimmunity33. Collectively, these macrophages exhibit increased expression and/or activity of the nuclear receptors, PPARγ and PPARδ, essential to their acquisition of alternative activation profile, associated with increased levels of arginase, certain receptors and anti-inflammatory cytokines27,28.

Here we observed that in vivo VIP treatment improves efferocytosis evaluated by two complementary approaches, the use of latex beads and apoptotic thymocytes. Moreover, we also observed an increased expression of TGF-β and PPARγ at the implantation sites.

In this sense, in a murine model of chronic granulomatous disease (CGD), which exhibits chronic inflammation and mild autoimmunity, macrophages maintain a pro-inflammatory profile associated with an impaired efferocytic ability and decreased expression of PPARγ34,35. In fact, the treatment with a PPARγ agonist in this mouse model of CGD, resolved prolonged zymosan-induced inflammation reflected by enhanced efferocytosis, and increased TGF-β and IL-10 production, highlighting a direct association between PPARγ increased expression and improved efferocytosis34. The macrophage PPARγ activation, increased efferocytic surface receptors and secretion of the bridge molecules, then enhanced efferocytic ability and the suppression of inflammation36.

These results also agree with previous data showing that VIP contributes to the switch of peritoneal macrophage predominant profile from an ‘inflammatory’ to a ‘regulatory’ phenotype at early pregnancy stages with increased production of IL-1037.

The cellular mechanisms that participate in VIP effect may involve multiple cells among which decidual cells and macrophages targeted by the peptide could contribute to a suitable immune tolerant microenvironment. Here, we show that the in vivo shift from inflammation to a pro-resolving state could be attributed, at least in part, to macrophages switching their programming in response to the changing milieu, suggesting that this peptide might be crucial to local homeostasis control at feto-maternal interface immunosuppressant mediators for adequate fetal growth.

Methods

Mice matings and treatment

An immunological model of exacerbated inflammation was represented by the mating combination CBA/J × DBA/2 and the combination CBA/J x BALB/c was used as a normal allogenic pregnancy (control mating). Mice were bred and maintained on a 12:12 h light–dark schedule in the Central Animal Care facility at the School of Exact and Natural Sciences, University of Buenos Aires (FCEyN-UBA).

Two-month-old CBA/J females were paired with BALB/c or DBA/2 males, checked daily for vaginal plugs and separated once mated. The day of the vaginal plug was considered as day 0.5 of pregnancy. The animals included in the first part of the study received no treatment. In the second part of the study, pregnant CBA/J females mated with DBA/2 or BALB/c were treated with phosphate-buffered saline (PBS) intraperitoneally or with VIP (2 nmol/mouse) at day 6.5 of gestation. Pregnant females were killed at day 8.5 of gestation. All studies were conducted according to standard protocols and were approved by the Animal Care and Use Committee of the School of Sciencies, University of Buenos Aires. An asymmetry function was used to assess the effect of VIP on the distribution of impanted embryos along the horns, taking into account the number of embryo and the distance in each horn.

Uterus and implantation site isolation for functional studies

Pregnant uteri were carefully dissected at day 8.5 of pregnancy and implantation sites were defined as previously described37 and isolated for cytokine and transcription factors measurement23. Explants of implantation sites (inlcuded placenta, decidua and mesometrial lymphoied aggregate of pregnacy, MLAp tissue) were excised, embryos discarded and tissues were incubated at 37 °C and 5%CO2 with VIP (100 nM) (Polypeptide labs, France) or not. Sites with viable embryos and sites with incipient resorption processes at gestational day 8.5 were assessed under magnifying glass, quantified to calculate resorption rate and photographed to show embryo distribution along horns among other gestation outcome signs as previously described12,23.

VIP/VPAC, Foxp3, RORγt and pro/anti inflammatory mediator detection

The expression of VIP and VPAC receptors, transcription factors and pro/anti inflammatory mediators was determined by RT-PCR. Briefly, total RNA was isolated following manufacturer recommendations with Trizol reagent (Life Technologies, Grand Island, NY, USA), cDNAs were generated from 1 ug or RNA using a MMLV reverse transcriptase, RNAsin RNAse inhibitor and oligodT kit (Promega Corporation, Madison, WI, USA) and stored at −20 °C for batch analysis. The sample volume was increased to 25 ul with the solution containing 50 mM KCl; 10 mM Tris (pH 8.3); 1.5 mM MgCl2; 0.1 mM forward and reverse primers of VIP, VPAC1, VPAC2, TGF-β, IL-17, PPRγ, Foxp3, RORγT and GAPDH as internal control (described in Table 1) and 1 U Taq polymerase in a DNA Thermocycler (PerkinElmer/Cetus, Boston, MA, USA). PCR products were electrophoresed through a 2% ethidium bromide-stained agarose gel, visualized by transillumination and scanned. Densitometry was performed using ImageJ 1.47 software (NIH, USA) and results expressed as arbitrary units normalized to GAPDH expression. Each assay included a DNA minus control and a standard curve performed with serial dilutions of control cDNA.

Table 1. Primers used in RT-PCR assays.

Primers Forward Reverse
GAPDH TGATGACATCAAGAAGGTGGTGAAG TCCTTGGAGGCCATGTAGGCCAT
VIP TTCACCAGCGATTACAGCAG TCACAGCCATTTGCTTTCTG
VPAC1 GTGAAGACCGGCTACACCAT TGAAGAGGGCCATATCCTTG
VPAC2 GTGAAGACCGGCTACACCAT TGAAGAGGGCCATATCCTTG
PPARγ ATC TAC ACG ATG CTG GC GGA TGT CCT CGA TGG
TGF-β GACTCTCCACCTGCAAGACCA TTGGGGGACTGGCGAGCCTT
Foxp3 GGCCCTTCTCCAGGACAGA GCTGATCATGGCTGGGTTGT
IL-17 CTCCAGAAGGCCCTCAGACTAC AGCTTTCCCCTCCGCATTGACACAG
RORγt CACGGCCCTGGTTCTCAT CAGATGTTCCACTCTCCTCTTCTCT
Open in a new tab

Oligonucleotide primers were designed using the online tool Primer3® (Whitehead Institute for Biomedical Research).

Peritoneal macrophages isolation

Macrophages were obtained from pregnant CBA/J × DBA/2 mice at day 8.5, treated with PBS or VIP at day 6.5. The peritoneal cavity was washed with ice-cold HANKS as reported38 were resuspended in RPMI 10% fetal calf serum (FCS) (Natocor Life Technologies, MD) and seeded in 24-well plates (Corning Glass, Corning, NY) at 5 × 105 cells/well. After incubation at 37 °C for 2 h, monolayers (>95% macrophages by F4/80 flow cytometry staining) were used for phagocytosis assays.

Efferocytosis assays

To evaluate the efferocytosis ability we used two complementary approaches, the phagocytosis of latex beads-FITC and of apoptotic thymocytes.

Efferocytosis of latex beads-FITC. Peritoneal macrophages recovered from CBA/J × DBA/2 female at 8.5 day of gestation were cultured with latex beads (1–3 μm) FITC-conjugated in the absence or presence of VIP (10 nM) in a 1:100 ratio (macrophage:beads). Incubations were performed at 37 °C with 5% CO2 in 24-well plates and after 90 min macrophages were recovered by Triple® (Gybco, Invitrogen, Argentina) and the percentage of efferocytosis was quantified by FACS analysis. Results are expressed as % of FITC+ cells.

Efferocytosis of apoptotic thymocytes. Thymocytes were obtained from syngeneic mice of 21 days of age, were thoroughly washed and induced to apoptosis with 100 nM dexamethasone for 4 h at 37 °C38. Then macrophages were co-cultured with syngeneic thymocytes previously induced to apoptosis (ratio 1:5 macrophage: thymocytes). Incubations were run at 37 °C on coverslips placed inside 24-well plates for the indicated times (30, 60, 90 and 120 min), then stained with Hematoxilin–Eosin and analyzed by microscopy. Results are expressed as the % of efferocytosis and the phagocytic index determination representing the number of apoptotic bodies phagocytized by each macrophage38.

Cytokine quantification

After the efferocytosis assay, macrophages from pregnant CBA/J females treated with PBS or VIP were washed and remained in culture for additional 24 h and then supernatants were collected for cytokine determination. Cytokines were also evaluated before the efferocytosis assay in both groups of mice under study. ELISA for TNF-α and IL-12 (eBiosciences, USA) were performed according to the manufacturer’s protocols. The limits of detection were 8 pg/ml for TNF-α and 4 pg/ml for IL-12. Results were expressed in pg/ml.

Flow-cytometric analysis

Intracellular staining for IL-10 detection

IL-10 production was quantified in macrophages of pregnant CBA/J females after in vivo treatment with PBS or VIP before and after efferocytosis. In the last 4 h of the assay, Stop Golgi (BD, Pharmigen, San José, CA, USA) was added to the culture to promote IL-10 intracellular accumulation. Then macrophages were recovered and after washing, cells were stained with anti-F4/80-FITC mAb for 30 min, fixed with Cytofix/cytoperm (BD, Pharmigen, San José, CA, USA) at room temperature and incubated for 30 min with anti-IL10-PE mAb (eBiosciece, USA).

Ten thousand events were acquired in a FACSAria cytometer® and results were analyzed using the FlowJo software®. Negative control samples were incubated in parallel with an irrelevant isotype-matched antibody. Results for positive cells are expressed as a percentage of F4/80 + IL-10+ cells.

Statistical analysis

Statistical significance of differences was determined by the two-tailed t test for independent populations and Student’s t test for parametric analysis. When multiple comparisons were necessary, the Student-Newman-Keuls test was used after analysis of variance. For in-vivo treatment experiments, the Mann-Whitney Test was used. Statistical significance was defined as p < 0.05, using the GraphPad Prism6 software (GraphPad, San Diego, CA, USA).

Additional Information

How to cite this article: Gallino, L. et al. VIP treatment prevents embryo resorption by modulating efferocytosis and activation profile of maternal macrophages in the CBAxDBA resorption prone model. Sci. Rep. 6, 18633; doi: 10.1038/srep18633 (2016).

Acknowledgments

This study was supported by grants to RR and CPL (CONICET PIP 0602/12, UBACyT 2014-2017 and 2012-2015 from University of Buenos Aires and PICT 0144/11 and PICT 1632/13 from ANPCyT).

Footnotes

Author Contributions C.P.L. and R.R. designed the study, supervised the experimental work and wrote the manuscript. L.G. and G.C. carried out all the experiments with the mice models. L.F. and V.H. performed the efferocytosis assays. M.V. carried out the cytokine quantification and E.G. helped with RT-PCRs data analysis and interpretation. C.P.L. and R.R. supervised the whole study. All authors read and approved the final manuscript.

References

  1. Dekel N., Gnainsky Y., Granot I. & Mor G. Inflammation and implantation. Am. J. Immunol. 63, 17–21 (2010) [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Weiss G., Goldsmith L. T., Taylor R. N., Bellet D. & Taylor H. S. Inflammation in reproductive disorders. Reprod Sciences 16, 216–229 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Gomez-Lopez N., Guilbert L. J. & Olson D. M. Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J. Leuk. Biol. 88, 625–633 (2010). [DOI] [PubMed] [Google Scholar]
  4. Mor G. & Cardenas I. The immune system in pregnancy: a unique complexity. Am. J. Reprod. Immunol. 63, 425–433 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Nagamatsu T. & Schust D. J. The contribution of macrophages to normal and pathological pregnancies. Am. J. Reprod. Immunol. 63, 460–471 (2010). [DOI] [PubMed] [Google Scholar]
  6. Salamone G. et al. Trophoblast cells induce a tolerogenic profile in dendritic cells. Hum. Reprod. 27, 2598–2606 (2012). [DOI] [PubMed] [Google Scholar]
  7. Teles A. et al. Origin of Foxp3(+) cells during pregnancy. Am J Clin Exp Immuno 2, 222–233 (2013). [PMC free article] [PubMed] [Google Scholar]
  8. Pérez Leirós C. & Ramhorst R. Tolerance induction at the early maternal-placental interface through selective cell recruitment and targeting by immune polypeptides. Am. J. Reprod. Immunol. 69, 359–368 (2013). [DOI] [PubMed] [Google Scholar]
  9. Yoshinaga K. Progesterone and Its Downstream Molecules as Blastocyst Implantation Essential Factors. Am. J. Reprod. Immunol. 4, 117–128 (2014). [DOI] [PubMed] [Google Scholar]
  10. Robertson S. A., Prins J. R., Sharkey D. J. & Moldenhauer L. M. Seminal fluid and the generation of regulatory T cells for embryo implantation. Am. J. Reprod. Immunol. 69, 315–330 (2013). [DOI] [PubMed] [Google Scholar]
  11. Fraccaroli L. et al. Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. Clin.Exp. Immunol. 170, 310–320 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Hauk V. et al. Vasoactive intestinal peptide induces an immunosuppressant microenvironment in the maternal-fetal interface of non-obese diabetic mice and improves early pregnancy outcome. Am. J. Reprod. Immunol. 71, 120–130 (2014). [DOI] [PubMed] [Google Scholar]
  13. Santner-Nanan B. et al. Systemic increase in the ratio between Foxp3+ and IL-17-producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J. Immunol. 183, 7023–7030 (2009). [DOI] [PubMed] [Google Scholar]
  14. D’Addio F. et al. The link between the PDL1 costimulatory pathway and Th17 in fetomaternal tolerance. J Immunol. 1, 4530–4541 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Abad C., Tan Y. V., Cheung-Lau G., Nobuta H. & Waschek J. A. VIP deficient mice exhibit resistance to lipopolysaccharide induced endotoxemia with an intrinsic defect in proinflammatory cellular responses. PLoS One 7, e36922 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mjosberg J., Berg G., Jenmalm M. C. & Ernerudh J. FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol. Reprod. 82, 698–705 (2009). [DOI] [PubMed] [Google Scholar]
  17. Mantovani A., Biswas S. K., Galdiero M. R., Sica A. & Locati M. Macrophage plasticity and polarization in tissue repair and remodelling. J Pathol. 229, 176–185 (2013). [DOI] [PubMed] [Google Scholar]
  18. Fest S. et al. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol. 57, 55–66 (2007). [DOI] [PubMed] [Google Scholar]
  19. Delgado M., Munoz-Elias E. J., Gomariz R. P. & Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J. Iimmunol 162, 4685–4696 (1999). [PubMed] [Google Scholar]
  20. Gomariz R. P. et al. Regulation of TLR expression, a new perspective for the role of VIP in immunity. Peptides 28, 1825–1832 (2007). [DOI] [PubMed] [Google Scholar]
  21. Gonzalez-Rey E., Anderson P. & Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Annals Rheum. Dis. 66 Suppl 3, iii70–76 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Jimeno R. et al. Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol. Cell Biol. 90, 178–186 (2012). [DOI] [PubMed] [Google Scholar]
  23. Roca V. et al. Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction 138, 733–742 (2009). [DOI] [PubMed] [Google Scholar]
  24. Zenclussen A. C. et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am. J. Pathol. 166, 811–822 (2005). [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Clark D. A., Chaouat G., Arck P. C., Mittruecker H. W. & Levy G. A. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase J. Immunol. 15, 545–549 (1998). [PubMed] [Google Scholar]
  26. Girardi G., Yarilin D., Thurman J. M., Holers V. M. & Salmon J. E. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J. Exp. Med. 203, 2165–2175 (2006). [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Bouhlel M. A. et al. PPARgamma activation primes human monocytes into alternative M2 macrophages with anti-inflammatory properties. Cell Metab. 6, 137–143 (2007). [DOI] [PubMed] [Google Scholar]
  28. Odegaard J. I. et al. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 447, 1116–1120 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Racicot K., Kwon J.-Y., Aldo P., Silasi M. & Mor G. Understanding the Complexity of the Immune System during Pregnancy. Am. J. Reprod. Immunol. 72, 107–116 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Roca V. et al. Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice. Reproduction 132, 931–938 (2006). [DOI] [PubMed] [Google Scholar]
  31. Obermajer N. et al. Conversion of Th17 into IL-17A(neg) regulatory T cells: a novel mechanism in prolonged allograft survival promoted by mesenchymal stem cell-supported minimized immunosuppressive therapy. J.Immunol. 193, 4988–4999 (2014). [DOI] [PubMed] [Google Scholar]
  32. Chen Q. et al. Navigating the site for embryo implantation: Biomechanical and molecular regulation of intrauterine embryo distribution. Mol. Asp. Med. 34, 1024–1042 (2013). [DOI] [PubMed] [Google Scholar]
  33. Schif-Zuck S. et al. A. Saturated-efferocytosis generates pro-resolving CD11b low macrophages: modulation by resolvins and glucocorticoids. Eur. J. Immunol. 41, 366–379 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Fernandez-Boyanapalli R. et al. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 116, 4512–4522 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. Fernandez-Boyanapalli R. F. et al. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 113, 2047–2055 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Korns D., Frasch S. C., Fernandez-Boyanapalli R., Henson P. M. & Bratton D. L. Modulation of macrophage efferocytosis in inflammation. Fron.Immunol. 2, 57. (2011) [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Pang S. In The Guide to Investigation of Mouse Pregnancy (ed. Croy A.) 21–42 (Elsevier Inc., 2014). [Google Scholar]
  38. Larocca L. et al. Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol. Cell. Endocrinol. 333, 112–118 (2011). [DOI] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES